PP / MONOGRAPH 010 Peptide or related research compound

B7-33

Discovery history, preclinical evidence, human studies, current FDA context, and the questions that still need to be answered.

Evidence is not equivalence.

Research on a named molecule does not establish that a catalog material is the studied drug product. Identity, sequence, salt, formulation, purity, sterility, route, labeling, and indication can change the scientific and regulatory conclusion.

ORIGIN / HISTORY

When was B7-33 first described?

B7-33 was described by Hossain and colleagues in the Bathgate research group in 2016 as a single-chain relaxin-family peptide agonist designed to bias RXFP1 signaling. [1]

PRECLINICAL EVIDENCE

What do animal and laboratory studies show?

Preclinical (fibrosis, cardiac). Evidence for the exact named material or blend remains preclinical, indirect, or absent. [2]

Translation limitCell and animal findings can generate mechanisms and safety signals, but they do not predict clinical benefit on their own.

CLINICAL EVIDENCE

Are there human studies?

No qualifying human efficacy evidence was identified in the reviewed summary for the exact named material. A registry search is linked below so readers can check current recruiting, completed, terminated, or unpublished studies. [2][3]

Check the live study registry ↗

U.S. REGULATORY STATUS

Is B7-33 FDA cleared or approved?

Drug terminology: FDA generally approves drug products; “clearance” is typically a medical-device pathway.

This review does not identify an FDA-approved drug product corresponding to the catalog name B7-33. That statement is not a legal determination and does not replace a current product-specific search of Drugs@FDA, applicable biologics databases, or jurisdiction-specific rules. [4][5]

RESEARCH OUTLOOK

Where is the scientific promise?

The scientific promise of B7-33 is a hypothesis for further testing, not a demonstrated product benefit. Useful next steps would include independent replication, validated identity and purity, dose–response and toxicology work, pharmacokinetics, prespecified endpoints, and properly registered human trials before clinical conclusions are drawn. [2][3]

LIMITATIONS / PRECAUTIONS

What should professionals keep in view?

No human data; unproven. [2]

Professional-use boundary

This page does not provide a diagnosis, treatment recommendation, protocol, dose, reconstitution instruction, route, or administration schedule. Any lawful program requires independent regulatory, quality, toxicology, and clinical review.

SOURCE REGISTER

References and live evidence maps

Primary papers support specific historical claims where available. PubMed and ClinicalTrials.gov links are live evidence maps, not proof that every result applies to the exact catalog material. FDA links should be rechecked because regulatory pages and product labels can change.